Optimization of the auxiliary ligand shell of cobalt(III)(8- hydroxyquinoline) complexes as model hypoxia-selective radiation-activated prodrugs

Radiation Research

Volumn 162, Issue 3, 2004, Pages 315-325

  Ahn, G One ^a   Ware, David C ^a   Denny, William A ^a   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7 TRIAZACYCLONONANE; 1,4,7,10 TETRAAZACYCLODODECANE; 8 QUINOLINOL; ALKYLATING AGENT; COBALT COMPLEX; DODECANE; HETEROCYCLIC COMPOUND; LIGAND; MACROCYCLIC COMPOUND; OXYGEN; PRODRUG; SN 24771; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYPOXIA; IONIZING RADIATION; MASS SPECTROMETRY; NONHUMAN; PLASMA; PRIORITY JOURNAL; RADIATION; STOICHIOMETRY; TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; CHO CELLS; COBALT; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIGANDS; MICE; OXYQUINOLINE; PRODRUGS;

EID: 4644296027     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR3229     Document Type: Article

References (49)

1. R. A. Gatenby, H. B. Kessler, J. S. Rosenblum, L. R. Coia, P. J. Moldofsky, W. H. Hartz and G. J. Broder, Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 14, 831-838 (1988).
2. 2 predicts survival in advanced cancer of the uterine cervix. Radiother. Oncol. 26, 45-50 (1993).
3. M. Nordsmark, M. Overgaard and J. Overgaard, Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 41, 31-39 (1996).
4. A. W. Fyles, M. Milosevic, R. Wong, M. C. Kavanagh, M. Pintilie, A. Sun, W. Chapman, W. Levin, L. Manchul and R. P. Hill, Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol. 48, 149-156 (1998).
5. E. K. Rofstad, K. Sundfor, H. Lyng and C. G. Trope, Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br. J. Cancer 83, 354-359 (2000).
6. J. M. Brown and A. J. Giaccia, The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res. 58, 1408-1416 (1998).
7. J. M. Brown and W. R. Wilson, Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 4, 437-447 (2004).
8. S. Rockwell, Use of hypoxia-directed drugs in the therapy of solid tumors. Semin. Oncol. 19, 29-40 (1992).
9. W. A. Denny, W. R. Wilson and M. P. Hay, Recent developments in the design of bioreductive drugs. Br. J. Cancer 27 (Suppl.), S32-S38 (1996).
10. A. M. Rauth, T. Melo and V. Misra, Bioreductive therapies: An overview of drugs and their mechanisms of action. Int. J. Radiat. Oncol. Biol. Phys. 42, 755-762 (1998).
11. I. J. Stratford and P. Workman, Bioreductive drugs into the next millennium. Anticancer Drug Des. 13, 519-528 (1998).
12. P. Wardman, Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr. Med. Chem. 8, 739-761 (2001).
13. 2 inhibition of nitroreductase. Biochem. Biophys. Res. Commun. 67, 1267-1274 (1975).
14. B. G. Sum and W. R. Wilson, Efficient redox cycling of nitroquinoline bioreductive drugs due to aerobic nitroreduction in Chinese hamster cells. Biochem. Pharmacol. 50, 75-82 (1995).
15. J. von Pawel, R. von Roemeling, U. Gatzemeier, M. Boyer, L. O. Elisson, P. Clark, D. Talbot, A. Rey, T. W. Butler and J. Treat, Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J. Clin. Oncol. 18, 1351-1359 (2000).
16. D. Rischin, L. Peters, R. Hicks, P. Hughes, R. Fisher, R. Hart, M. Sexton, I. D'Costa and R. von Roemeling, Phase I trial of concurrent tirapazamine, cisplatin and radiotherapy in patients with advanced head and neck cancer. J. Clin. Oncol. 19, 535-542 (2001).
17. W. A. Denny and W. R. Wilson, Tirapazamine: A bioreductive anticancer drug that exploits tumour hypoxia. Expert Opin. Investig. Drugs 9, 2889-2901 (2000).
18. L. H. Patterson and S. R. McKeown, AQ4N: A new approach to hypoxia-activated cancer chemotherapy. Br. J. Cancer 83, 1589-1593 (2000).
19. M. V. Papadopoulou, M. Ji, X. Ji and W. D. Bloomer, Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; Comparison with tirapazamine. Cancer Chemother. Pharmacol. 50, 291-298 (2002).
20. K. O. Hicks, Y. Fleming, B. G. Sum, C. J. Koch and W. R. Wilson, Extravascular diffusion of tirapazamine: Effect of metabolic consumption assessed using the multicellular layer model. Int. J. Radiat. Oncol. Biol. Phys. 42, 641-649 (1998).
21. K. O. Hicks, F. B. Pruijn, J. R. Sturman, W. A. Denny and W. R. Wilson, Multicellular resistance to tirapazamine is due to restricted extravascular transport: A pharmacokinetic/pharmacodynamic study in HT29 multicellular layers. Cancer Res. 63, 5970-5977 (2003).
22. M. A. Breider, G. D. Pilcher, M. J. Graziano and A. W. Gough, Retinal degeneration in rats induced by CI-1010, a 2-nitroimidazole radiosensitizer. Toxicol. Pathol. 26, 234-239 (1998).
23. A. E. Lee and W. R. Wilson, Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol. Appl. Pharmacol. 163, 50-59 (2000).
24. R. J. Knox, F. Friedlos, M. Jarman and J. J. Robert, A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydrozylamino-2- nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitro-benzamide (CB1954) by nitroreductase enzyme in Walker carcinoma cells. Biochem. Pharmacol. 37, 4661-4669 (1988).
25. D. L. Gustafson and C. A. Pritsos, Kinetics and mechanism of mitomycin C bioactivation by xanthine dehydrogenase under aerobic and hypoxic conditions. Cancer Res. 53, 5470-5474 (1993).
26. J. A. Plumb, M. Gerritsen, R. Milroy, P. Thomson and P. Workman, Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines. Int. J. Radiat. Oncol. Biol. Phys. 29, 295-299 (1994).
27. W. R. Wilson, M. Tercel, R. F. Anderson and W. A. Denny, Radiation-activated prodrugs as hypoxia-selective cytotoxins: Model studies with nitroarylmethyl quaternary salts. Anticancer Drug Des. 13, 663-685 (1998).
28. D. L. Boger, W. Yun and N. Han, 1,2,9,9a-tetrahydrocyclopropa[c]benz[e] indol-4-one (CBI) analogs of CC-1065 and the duocarmycins: Synthesis and evaluation. Bioorg. Med. Chem. 3, 1429-1453 (1995).
29. G. J. Atwell, M. Tercel, M. Boyd, W. R. Wilson and W. A. Denny, Synthesis and cytotoxicity of 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl) carbonyl]-1,2-dihydro-3H-benz[e]indole (amino-seco-CBI-TMI) and related 5-alkylamino analogues: New DNA minor groove alkylating agents. J. Org. Chem. 63, 9414-9420 (1998).
30. A. G. Krisle, M. Tercel, S. M. Stribbling, K. J. Botting and W. R. Wilson, Radiation-activated prodrugs: Hypoxia-selective radiolytic release of potent chloromethylbenzindoline (CBI) cytotoxins from novel nitroarylmethyl quaternary (NMQ) prodrugs. Br. J. Cancer 86 (Suppl.), S30-S31 (2002).
31. R. F. Anderson, W. A. Denny, W Li, J. E. Packer, M. Tercel and W. R. Wilson, Pulse radiolysis studies on the fragmentation of arylmethyl quaternary nitrogen mustards by one-electron reduction in aqueous solution. J. Phys. Chem. 101, 9704-9709 (1997).
32. W. R. Wilson, D. M. Ferry, M. Tercel, R. F. Anderson and W. A. Denny, Reduction of nitroarylmethyl quaternary ammonium prodrugs of mechlorelhamine by radiation. Radiat. Res. 149, 237-245 (1998).
33. A. G. Kriste, M. Tercel, R. F. Anderson, D. M. Ferry and W. R. Wilson, Pathways of reductive fragmentation of heterocyclic nitroarylmethyl quaternary ammonium prodrugs of mechlorethamine. Radiat. Res. 158, 753-762 (2002).
34. D. C. Ware, B. D. Palmer, W. R. Wilson and W. A. Denny, Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards. J. Med. Chem. 36, 1839-1846 (1993).
35. D. C. Ware, H. R. Palmer, F. B. Pruijn, R. F. Anderson, P. J. Brothers, W. A. Denny and W. R. Wilson, Bis(dialkyl)dithiocarbamato cobalt(III) complexes of bidentate nitrogen mustards: Synthesis, reduction chemistry and biological evaluation as hypoxia-selective cytotoxins. Anticancer Drug Des. 13, 81-103 (1998).
36. R. F. Anderson, W. A. Denny, D. C. Ware and W. R. Wilson, Pulse radiolysis studies on the hypoxia-selective toxicity of a cobalt-mustard complex. Br. J. Cancer 27 (Suppl.), S48-S51 (1996).
37. D. C. Ware, P. J. Brothers, G. R. Clark, W. A. Denny, B. D. Palmer and W. R. Wilson, Synthesis, structures and hypoxia-selective cytotoxicity of cobalt(III) complexes containing tridentate amine and nitrogen mustard ligands. J. Chem. Soc. Dalton Trans. 925-932 (2000).
38. W. R. Wilson, J. W. Moselen, S. Cliffe, W. A. Denny and D. C. Ware, Exploiting tumor hypoxia through bioreductive release of diffusible cytotoxins: The cobalt(III)-nitrogen mustard complex SN 24771. Int. J. Radiat. Oncol. Biol. Phys. 29, 323-327 (1994).
39. L. F. Lindoy, The Chemistry of Macrocyclic Ligand Complexes. Cambridge University Press, Cambridge, 1991.
40. D. H. Busch, The compleat coordination chemistry - one practioner's perspective. Chem. Rev. 93, 847-860 (1993).
41. D. L. Boger and D. S. Johnson, CC-1065 and the duocarmycins: Understanding their biological function through mechanistic studies. Agnew Chem. Int. Ed. Engl 35, 1438-1474 (1996).
42. G. V. Buxton, Radiation chemistry of the liquid state: (1) water and homogenous aqueous solution. In Radiation Chemistry: Principles and Applications (Farhataziz and M. A. J. Rodgers, Eds.), pp. 321-349. VCH Publishers, New York, 1987.
43. Q. G. Mulazzani, M. D'Angelantonio, M. Venturi, M. Z. Huffman and M. A. J. Rodgers, Interaction of formate and oxalate ions with radiation-generated radicals in aqueous solution. Methylviologen as a mechanistic probe. J. Phys. Chem. 90, 5347-5352 (1986).
44. H. Fricke and E. J. Hart, Chemical dosimetry. In Radiation Dosimetry, Vol. 2 (F. H. Attix and W. C. Roesch, Eds.), pp. 167-239. Academic Press, New York, 1966.
45. D. Screnci, P. Galettis, B. C. Baguley and M. J. McKeage, Optimisation of an ICP-MS assay for the detection of trace levels of platinum in peripheral nerves. Atomic Spectrosc. 19, 172-175 (1998).
46. C. A. Hoy, E. P. Salazar and L. H. Thompson, Rapid detection of DNA-damaging agents using repair-deficient CHO cells. Mutat. Res. 130, 321-332 (1984).
47. W. R. Wilson, W. A. Denny, S. M. Pullen, K. M. Thompson, A. E. Li, L. H. Patterson and H. H. Lee, Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N. Br. J. Cancer 27 (Suppl.), S43-S47 (1996).
48. C. T. Dillon, P. A. Lay, A. M. Bonin, M. Cholewa and G. J. F. Legge, Permeability, cytotoxicity, and genotoxicity of Cr(III) complexes and some Cr(V) analogues in V79 Chinese hamster lung cells. Chem. Res. Toxicol. 13, 742-748 (2000).
49. F. G. Thomas and G. Henze, Introduction. In Introduction to Voltammetric Analysis: Theory and Practice (B. Hamilton, Ed.), pp. 1-17. CSIRO Publishing, Collingwood, 2001.